Physician profile
Adnan Ameer
NPI 1346554201
$6,391.55
in general payments reported to CMS, 2019-2025
24 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,167 · 2020: $281 · 2021: $420 · 2022: $217 · 2023: $399 · 2024: $1,711 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,307.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,567.43 | 2019-2024 | Autotome Rx 49 |
| Endogastric Solutions, INC | $1,085.03 | 2019 | |
| Abbvie INC. | $844.30 | 2020-2025 | Linzess, Viberzi, Creon |
| Apollo Endosurgery US INC | $692.74 | 2019 | |
| Ardelyx, INC. | $346.61 | 2023-2024 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.69 | 2022-2025 | Xifaxan, Trulance |
| Micro-Tech Endoscopy USA, INC. | $209.86 | 2019 | |
| Madrigal Pharmaceuticals | $178.54 | 2024 | Resmetirom |
| Cvrx, INC. | $169.05 | 2024 | Barostim Neo System |
| Celltrion USA INC. | $156.65 | 2024-2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $123.27 | 2024 | Voquezna |
| Gilead Sciences, INC. | $118.34 | 2019-2024 | |
| Qol Medical, LLC | $108.91 | 2024-2025 | Sucraid, Sucraid |
| Cook Medical LLC | $93.34 | 2020 | |
| Janssen Biotech, INC. | $81.02 | 2022-2024 | Tremfya, Stelara |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $70.52 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.44 | 2019-2023 | Entyvio |
| Ferring Pharmaceuticals INC. | $47.67 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $37.93 | 2023 | Dupixent |
| Echosens North America, INC. | $31.98 | 2024 | Fibroscan |
| Genzyme Corporation | $24.92 | 2024 | |
| Aimmune Therapeutics, INC. | $18.99 | 2024 | |
| Covidien LP | $17.79 | 2019 | |
| Welch Allyn | $17.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adnan Ameer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.